analysts Recommendations: Eli Lilly and Company (NYSE:LLY)


Eli Lilly and Company (NYSE:LLY) will report its next earnings on 31-Jan-17. The company reported the earnings of $0.88/Share in the last quarter where the estimated EPS by analysts was $0.96/share. The difference between the expected and actual EPS was $-0.08/share, which represents an Earnings surprise of -8.3%.

Many analysts are providing their Estimated Earnings analysis for Eli Lilly and Company and for the current quarter 17 analysts have projected that the stock could give an Average Earnings estimate of $0.97/share. These analysts have also projected a Low Estimate of $0.87/share and a High Estimate of $1.03/share.

In case of Revenue Estimates, 15 analysts have provided their consensus Average Revenue Estimates for Eli Lilly and Company as 5.54 Billion. According to these analysts, the Low Revenue Estimate for Eli Lilly and Company is 5.39 Billion and the High Revenue Estimate is 5.73 Billion. The company had Year Ago Sales of 5.38 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for LLY to be 24.4%. They are projecting Next Quarter growth of 13.3%. For the next 5 years, Eli Lilly and Company is expecting Growth of 10.35% per annum, whereas in the past 5 years the growth was -3.26% per annum.

Some buy side analysts are also providing their Analysis on Eli Lilly and Company, where 6 analysts have rated the stock as Strong buy, 9 analysts have given a Buy signal, 6 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. 21 Analysts reported that the Price Target for Eli Lilly and Company might touch $110 high while the Average Price Target and Low price Target is $85.19 and $70 respectively.

To analyze a stock, one should look for Upgrades and Downgrades of a stock. Eli Lilly and Company got Upgrade on 16-Dec-16 where investment firm Morgan Stanley Upgrade the stock from Equal-Weight to Overweight.

Eli Lilly and Company closed its last trading session at $77.4 with the loss of -0.71%. The Market Capitalization of the company stands at 84.56 Billion. The Company has 52-week high of $83.79 and 52-week low of $64.18. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 3.25% where SMA50 and SMA200 are 5.64% and 1.26% respectively. The Company Touched its 52-Week High on Aug 1, 2016 and 52-Week Low on Nov 23, 2016.

The Relative Volume of the company is 0.8 and Average Volume (3 months) is 6.15 million. Eli Lilly and Company P/E (price to earnings) ratio is 33.37 and Forward P/E ratio of 18.74.

The company shows its Return on Assets (ROA) value of 6.8%. The Return on Equity (ROE) value stands at 16.3%. While it’s Return on Investment (ROI) value is 9.5%.

While looking at the Stock’s Performance, Eli Lilly and Company currently shows a Weekly Performance of 0.76%, where Monthly Performance is 13.57%, Quarterly performance is -2.42%, 6 Months performance is -2.63% and yearly performance percentage is -2.87%. Year to Date performance value (YTD perf) value is 4.49%. The Stock currently has a Weekly Volatility of 2.49% and Monthly Volatility of 1.80%.